TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension

Falls Church, Virginia - Retension Pharmaceuticals Inc. (NASDAQ:RTSN) has announced the pricing of its initial public offering on Wednesday. The company plans to sell 3,750,000 shares of common stock at a price of $12.00 per share. The clinical-stage biopharmaceutical firm anticipates gross proceeds of $45.0 million, after accounting for underwriting fees, commissions, and other costs associated with the offering.

Retension has reserved the right to purchase an additional 562,500 shares within 30 days of the initial offering, at the same price, also excluding underwriting discounts and commissions. The offering is anticipated to conclude on or around October 13, 2026, provided all necessary closing conditions are met. Shares of the company are poised to commence trading on the Nasdaq Capital Market under the ticker symbol RTSN, starting today.

Retension intends to utilize the net proceeds, combined with the company's current cash reserves, to finalize the Phase 2b clinical trial of its lead product, RTN-001, which targets uncontrolled hypertension. The company plans to initiate the Phase 3 clinical trial of RTN-001 thereafter. The remaining funds from the IPO will be allocated towards general corporate expenses and ongoing operational costs.

Retension Pharmaceuticals specializes in the development of medications for the management of hypertension and other cardiovascular diseases. Its primary clinical candidate, RTN-001, is being developed for patients suffering from uncontrolled and resistant hypertension. The offering's underwriters include Leerink Partners, Guggenheim Securities, and Oppenheimer & Co., with Titan Partners serving as the lead manager.

Registration statements pertaining to these securities became effective on October 8, 2026. This report has been prepared using AI assistance and has been thoroughly reviewed by an editor.